Listar GI-EIHS - Artigos por título
Mostrando ítems 8-13 de 13
-
Long-term benefits of nevirapine-containing regimens: multicenter study with 506 patients, followed-up a median of 9 years
(Bentham, 2012-09)[Abstract] OBJECTIVE: To evaluate long-term outcomes in patients maintaining a nevirapine (NVP)-based regimen. METHODS: Retrospective, multicenter, cohort study including patients currently receiving an NVP regimen that ... -
Neoplasias en pacientes con infección por VIH: estudio descriptivo de 129 casos en el período 1993-2010
(Sociedad Chilena de Infectología, 2013)[Resumen] Introducción: Uno de los problemas asociados a la infección por VIH es el desarrollo de neoplasias. La incidencia y espectro de los distintos cánceres se ha visto modificada con la incorporación del tratamiento ... -
Phylogeny and phylogeography of a recent HIV-1 subtype F outbreak among men who have sex with men in Spain deriving from a cluster with a wide geographic circulation in western Europe
(PLOS, 2015-11-24)[Abstract] We recently reported the rapid expansion of an HIV-1 subtype F cluster among men who have sex with men (MSM) in the region of Galicia, Northwest Spain. Here we update this outbreak, analyze near full-length ... -
Prevalencia de síntomas de asma y rinitis en la población de A Coruña
(Elsevier, 2007-02)[Resumen] Introducción. El asma y la rinitis son dos enfermedades con elevada prevalencia en la infancia, con tendencia a incrementarse en los últimos años. En ambas es frecuente el infradiagnóstico. Objetivo. Verificar ... -
Total HCV core antigen assay: a new marker of HCV viremia and its application during treatment of chronic hepatitis C
(Elsevier, 2004-06-15)[Abstract] The present study assesses the clinical usefulness of the hepatitis C core antigen assay for monitoring of patients being treated for chronic hepatitis C virus (HCV) infection. Eighty-six serum samples were ... -
Treatment with tenofovir alafenamide fumarate worsens the lipid profile of HIV‐infected patients versus treatment with tenofovir disoproxil fumarate, each coformulated with elvitegravir, cobicistat, and emtricitabine
(Wiley, 2018-11-02)[Abstract] Two elvitegravir/cobicistat‐based therapies combined with emtricitabine/tenofovir disoproxil fumarate (EVG/c/FTC/TDF) or emtricitabine/tenofovir alafenamide fumarate (EVG/c/FTC/TAF) are currently available for ...